Health Care • Industrial Specialties
$232.14 ▲ +3.36
(+1.47%)
MKT CAP: $22.63B • VOL: 485.9K
52W L $195 52W H $269
STE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.94B | $5.46B | $5.14B |
| YoY Revenue Growth % | +8.7% | +6.2% | — |
| Gross Profit | $2.63B | $2.40B | $2.26B |
| Gross Margin % | 44.2% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.10B | $866.6M | $836.1M |
| Operating Margin % | 18.6% | 15.9% | 16.3% |
| Net Income (GAAP) | $782.3M | $614.6M | $378.2M |
| EBITDA (Normalized) | $1.40B | $1.16B | $1.02B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.34B | $1.15B | $973.3M |
| Capital Expenditures (CapEx) | $369.0M | $370.1M | $231.2M |
| Free Cash Flow (FCF) | $972.4M | $778.0M | $742.1M |
| FCF Margin % | 16.4% | 14.3% | 14.4% |
| Return on Invested Capital (ROIC %) | 10.1% | 8.2% | 8.8% |
| Cash & Short-Term Equivalents | $423.7M | $155.2M | $1.37B |
| Total Debt (Short + Long Term) | $1.90B | $2.04B | $2.91B |
| Total Stockholders' Equity | $7.15B | $6.42B | $5.98B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR STE.